Biosimilar insulin glargine: Phase III started

Mylan began the open-label, U.S. Phase III INSTRIDE 2 trial to compare once-daily biosimilar insulin glargine vs. once-daily Lantus insulin glargine for 24 weeks in about 600 adult Type II diabetics ...